[PAR] [TLE] Crizanlizumab [SEP] Crizanlizumab is a monoclonal antibody developed by Novartis targeted towards P-selectin.  It was announced by the company as an effective drug to prevent vaso-occlusive crisis in patients with Sickle cell anemia.  The result of the Phase II SUSTAIN clinical trial was published on December 3, 2016 which showed the efficacy of the drug in sickle cell patients.  Trial was conducted among 196 patients over 12 months which showed reduction in annual rate of sickle cell crises by 45% compared to the placebo group. [PAR] [TLE] Novartis [SEP] Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland.  It is one of the largest pharmaceutical companies by both market cap and sales.
[PAR] [TLE] Crizanlizumab [ SEP ] Crizanlizumab is a monoclonal antibody developed by Novartis targeted towards P - selectin . It was announced by the company as an effective drug to prevent vaso - occlusive crisis in patients with Sickle cell anemia . The result of the Phase II SUSTAIN clinical trial was published on December 3 , 2016 which showed the efficacy of the drug in sickle cell patients . Trial was conducted among 196 patients over 12 months which showed reduction in annual rate of sickle cell crises by 45 % compared to the placebo group . [PAR] [TLE] Novartis [ SEP ] Novartis International AG is a Swiss multinational pharmaceutical company based in Basel , Switzerland . It is one of the largest pharmaceutical companies by both market cap and sales .
Where are the headquarters of the company that developed Crizanlizumab?
Where are the headquarters of the company that developed Crizanlizumab ?
Basel, Switzerland
Basel, Switzerland